Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
6.87
-0.58 (-7.79%)
At close: May 30, 2025, 4:00 PM
7.00
+0.13 (1.87%)
After-hours: May 30, 2025, 7:55 PM EDT

Intellia Therapeutics Stock Forecast

NTLA's stock price has decreased by -68.3% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 20 professional analysts, the 12-month price target for Intellia Therapeutics stock ranges from a low of $10 to a high of $90. The average analyst price target of $38.4 forecasts a 458.95% increase in the stock price over the next year.

Price Target: $38.40 (+458.95%)
Analyst Consensus: Buy
Target Low Average Median High
Price $10 $38.4 $41 $90
Change +45.56% +458.95% +496.80% +1210.0%

Analyst Ratings

The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Dec '24Jan '25Feb '25Mar '25Apr '25May '25
Strong Buy 555667
Buy 776677
Hold 566666
Sell 000000
Strong Sell 000000
Total 171817181920

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$30
Strong Buy Reiterates $30 +336.68% May 29, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$30
Strong Buy Reiterates $30 +336.68% May 20, 2025
Wedbush
Wedbush
Hold
Reiterates
$10
Hold Reiterates $10 +45.56% May 19, 2025
Guggenheim
Guggenheim
Strong Buy
Maintains
$55$45
Strong Buy Maintains $55$45 +555.02% May 12, 2025
Citigroup
Citigroup
Hold
Maintains
$14$10
Hold Maintains $14$10 +45.56% May 9, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
57.74M
from 57.88M
Decreased by -0.23%
Revenue Next Year
50.43M
from 57.74M
Decreased by -12.66%
EPS This Year
-4.28
from -5.25
EPS Next Year
-4.07
from -4.28
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
57.99M33.05M52.12M36.28M57.88M57.74M50.43M325.17M
Revenue Growth
34.55%-43.01%57.69%-30.40%59.55%-0.23%-12.66%544.77%
EPS
-2.40-3.78-6.16-5.42-5.25-4.28-4.07-3.68
EPS Growth
--------
Forward PE
--------
No. Analysts
-----292819
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 220.5M 105.0M 4.0B
Avg 57.7M 50.4M 325.2M
Low n/a 6.9M 3.6M

Revenue Growth

Revenue Growth 20252026202720282029
High
281.0%
81.8%
7,783.9%
Avg
-0.2%
-12.7%
544.8%
Low -
-88.1%
-92.9%

EPS Forecast

EPS 20252026202720282029
High -2.50 -2.27 -1.72
Avg -4.28 -4.07 -3.68
Low -4.96 -5.44 -5.20

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.